Results 271 to 280 of about 1,443,667 (357)

Structural insight into interleukin-4Rα and interleukin-5 inhibition by nanobodies from a bispecific antibody. [PDF]

MedComm (2020)
Qiu W, Meng J, Su Z, Xie W, Song G.
europepmc   +1 more source

A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib. [PDF]

Cell Rep Med
Simoni-Nieves A, Lindzen M, Giri S, Gupta N, Chatterjee R, Selvadurai BR, Van Daele M, Love D, Haga Y, Romaniello D, Salame TM, Zerbib M, Oren R, Tsutsumi Y, Lauriola M, Marrocco I, Yarden Y.   +16 more
europepmc   +1 more source

NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control. [PDF]

Cancer Immunol Res
Majocchi S, Lloveras P, Nouveau L, Legrand M, Viandier A, Malinge P, Charreton M, Raymond C, Pace EA, Millard BL, Svensson LA, Kelpšas V, Anceriz N, Salgado-Pires S, Daubeuf B, Magistrelli G, Gueneau F, Moine V, Masternak K, Shang L, Fischer N, Ferlin WG.   +21 more
europepmc   +1 more source

FLT3/CD99 Bispecific Antibody-Based Nanoparticles for Acute Myeloid Leukemia. [PDF]

Cancer Res Commun
Ali A, Phan A, Vaikari V, Park M, Pospiech M, Chu R, Meng Y, MacKay JA, Alachkar H.   +8 more
europepmc   +1 more source

IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy. [PDF]

Heliyon
Yang C, Li S, Chen D, Liu D, Yang Y, Guo H, Sun N, Bai X, Li G, Zhang R, Wang T, Zhang L, Peng L, Liu S, Zhang W, Zhao G, Tu X, Tian W.   +17 more
europepmc   +1 more source

Severe dual fungal infection after bispecific antibody therapy: A case of invasive aspergillosis and mucormycosis in immunocompromised patient. [PDF]

IDCases
Sakalihasan S, Lifrange F, Czajkowski M, Goncette V, Duysinx B, Lovinfosse P, Can D, Schils R, Hayette MP, De Voeght A.   +9 more
europepmc   +1 more source

A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology. [PDF]

Neurotherapeutics
Sehlin D, Roshanbin S, Zachrisson O, Ingelsson M, Syvänen S.   +4 more
europepmc   +1 more source

Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD-1 and VEGF, in Chinese Patients With Advanced Solid Tumors. [PDF]

Cancer Med
Wang F, Wei X, Zheng Y, Wang J, Ying J, Chen X, Luo S, Luo H, Yu X, Chen B, Ma L, Xu R.   +11 more
europepmc   +1 more source

Retargeting of Human Regulatory T Cells by Single-Chain Bispecific Antibodies

, 2011
Stefanie Koristka, Marc Cartellieri, Anke Theil, Anja Feldmann, Claudia Arndt, Slava Stamova, Irene Michalk, Katrin Töpfer, Achim Temme, Karsten Kretschmer, Martin Bornhäuser, Gerhard Ehninger, Marc Schmitz, Michael Bachmann   +13 more
openalex   +1 more source

Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy. [PDF]

Mater Today Bio
Xue F, Ren X, Kong C, Wang J, Liu L, Hu J, Shen N, Tang Z.   +7 more
europepmc   +1 more source